Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.50 |
| ▸ | GPR52 | Q9Y2T5 | 7/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439128 | 0.91 | PDE2A (0.48) | PDE2AGPR52KDM4AKDM5AIRAK4 | |
| SCHEMBL14033150 | 0.87 | KDM5A (0.53) | PDE2AKDM4AKDM5AIRAK4PDE3A | |
| SCHEMBL4555621 | 0.84 | GPR52 (0.50) | PDE2AGPR52IRAK4PDE10AJAK2 | |
| SCHEMBL4555125 | 0.81 | IRAK4 (0.43) | PDE2AIRAK4JAK2 | |
| SCHEMBL14033866 | 0.78 | PDE2A (0.45) | PDE2AGPR52IRAK4PDE10AJAK2 | |
| SCHEMBL14048912 | 0.78 | PDE2A (0.44) | PDE2AIRAK4PDE10A | |
| SCHEMBL14033688 | 0.77 | PDE2A (0.46) | PDE2AIRAK4 | |
| SCHEMBL4553722 | 0.77 | IRAK4 (0.43) | PDE2AIRAK4 | |
| SCHEMBL14033858 | 0.77 | PDE2A (0.42) | PDE2AIRAK4JAK2 | |
| SCHEMBL14033167 | 0.77 | PDE2A (0.41) | PDE2AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137187-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | Inovacia AB (SE) | 2009-12-30 | — | — | EP | claimed |
| WO-2008116898-A1 | PYRAZOLO [1,5-A]PYRIMIDINES AS INHIBITORS OF STEAROYL-COA DESATURASE | BIOVITRUM AB (PUBL) (SE) | 2008-10-02 | — | — | WO | claimed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255153-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255153-A1 | New compounds | SCD, SCD5, FADS2 | PDE2A 2511/4885GPR52 1409/4885KDM4A 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.